191 related articles for article (PubMed ID: 38315270)
1. Prediction of [
Ha S; Kim YI; Oh JS; Yoo C; Ryoo BY; Ryu JS
EJNMMI Phys; 2024 Feb; 11(1):14. PubMed ID: 38315270
[TBL] [Abstract][Full Text] [Related]
2. Relationships between uptake of [
Stenvall A; Gustafsson J; Larsson E; Roth D; Sundlöv A; Jönsson L; Hindorf C; Ohlsson T; Sjögreen Gleisner K
EJNMMI Res; 2022 Dec; 12(1):75. PubMed ID: 36534192
[TBL] [Abstract][Full Text] [Related]
3. Correlations between [
Bruvoll R; Blakkisrud J; Mikalsen LT; Connelly J; Stokke C
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831477
[TBL] [Abstract][Full Text] [Related]
4. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of pretherapy [
Akhavanallaf A; Peterson AB; Fitzpatrick K; Roseland M; Wong KK; El-Naqa I; Zaidi H; Dewaraja YK
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2984-2996. PubMed ID: 37171633
[TBL] [Abstract][Full Text] [Related]
6. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
7. Comparison of
Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of peptide receptor radionuclide therapy with
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
[No Abstract] [Full Text] [Related]
9. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
Opalińska M; Morawiec-Sławek K; Kania-Kuc A; Al Maraih I; Sowa-Staszczak A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2022; 13():929391. PubMed ID: 36046793
[TBL] [Abstract][Full Text] [Related]
10. Comparison of [
Veenstra EB; Brouwers AH; de Groot DJA; Hofland J; Walenkamp AME; Brabander T; Zandee WT; Noordzij W
Eur J Hybrid Imaging; 2022 Jun; 6(1):12. PubMed ID: 35701566
[TBL] [Abstract][Full Text] [Related]
11. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
Huizing DMV; Aalbersberg EA; Versleijen MWJ; Tesselaar MET; Walraven I; Lahaye MJ; de Wit-van der Veen BJ; Stokkel MPM
Cancer Imaging; 2020 Aug; 20(1):57. PubMed ID: 32778165
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
[TBL] [Abstract][Full Text] [Related]
13. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
14. Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT).
Chicheportiche A; Artoul F; Schwartz A; Grozinsky-Glasberg S; Meirovitz A; Gross DJ; Godefroy J
EJNMMI Phys; 2018 Jun; 5(1):10. PubMed ID: 29916115
[TBL] [Abstract][Full Text] [Related]
15. First-in-Humans Study of the SSTR Antagonist
Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
[TBL] [Abstract][Full Text] [Related]
16. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
[TBL] [Abstract][Full Text] [Related]
17. Predictive power of the post-treatment scans after the initial or first two courses of [
Chicheportiche A; Grozinsky-Glasberg S; Gross DJ; Krausz Y; Salmon A; Meirovitz A; Freedman N; Godefroy J
EJNMMI Phys; 2018 Dec; 5(1):36. PubMed ID: 30535780
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
[TBL] [Abstract][Full Text] [Related]
19. Response to Single Low-dose
Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X
Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731
[No Abstract] [Full Text] [Related]
20. Clinical implementation of PLANET® Dose for dosimetric assessment after [
Santoro L; Pitalot L; Trauchessec D; Mora-Ramirez E; Kotzki PO; Bardiès M; Deshayes E
EJNMMI Res; 2021 Jan; 11(1):1. PubMed ID: 33394212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
